1. Home
  2. SNY
  3. SNY News

Latest Sanofi ADS (SNY) News on March 30, 2025

Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
SNY

GlobeNewswire

2 days ago

Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

SNY

MT Newswires

2 days ago

Sanofi Hemophilia Treatment Receives FDA Approval

US FDA approves Sanofi's bleeding disorder therapy
SNY

Reuters

2 days ago

US FDA approves Sanofi's bleeding disorder therapy

FDA approves first-of-its-kind RNA drug for hemophilia
SNY

BioPharma Dive

2 days ago

FDA approves first-of-its-kind RNA drug for hemophilia

SNY

MT Newswires

2 days ago

Regeneron, Sanofi Say Japan Grants Marketing Authorization for Dupixent

Innate Pharma SA (IPHA) (FY 2024) Earnings Call Highlights: Strategic Advances and Financial ...
SNY

GuruFocus.com

2 days ago

Innate Pharma SA (IPHA) (FY 2024) Earnings Call Highlights: Strategic Advances and Financial ...

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
SNY

GlobeNewswire

2 days ago

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
SNY

GlobeNewswire

2 days ago

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

SNY

Morningstar Research

3 days ago

Analyst Report: Sanofi

Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive
SNY

Zacks

3 days ago

Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive

U.S. to end funding for child vaccines in developing countries, NY Times reports
SNY

TipRanks

3 days ago

U.S. to end funding for child vaccines in developing countries, NY Times reports

Sanofi’s chief digital officer says remote work means employees lose the ‘serendipity’ needed to innovate
SNY

Fortune

3 days ago

Sanofi’s chief digital officer says remote work means employees lose the ‘serendipity’ needed to innovate

SNY

Morningstar Research

4 days ago

Analyst Report: Sanofi

Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag
SNY

Zacks

4 days ago

Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag

FDA fast tracks Sanofi’s mRNA vaccine for chlamydia
SNY

Pharmaceutical Technology

4 days ago

FDA fast tracks Sanofi’s mRNA vaccine for chlamydia

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
SNY

Zacks

4 days ago

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)

Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
SNY

GlobeNewswire

4 days ago

Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib
SNY

Zacks

5 days ago

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib

Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
SNY

GlobeNewswire

5 days ago

Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis

Press Release: Availability of the Q1 2025 Aide mémoire
SNY

GlobeNewswire

6 days ago

Press Release: Availability of the Q1 2025 Aide mémoire

Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals
SNY

Zacks

9 days ago

Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

FedEx downgraded, Adobe upgraded: Wall Street's top analyst calls
SNY

The Fly

9 days ago

FedEx downgraded, Adobe upgraded: Wall Street's top analyst calls

Banks Launch €7.45 Billion Debt Sale for Sanofi Unit Buyout
SNY

Bloomberg

9 days ago

Banks Launch €7.45 Billion Debt Sale for Sanofi Unit Buyout

Sanofi outlays $1.9bn to purchase Dren Bio’s bispecific antibody
SNY

Pharmaceutical Technology

10 days ago

Sanofi outlays $1.9bn to purchase Dren Bio’s bispecific antibody

Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug
SNY

Zacks

10 days ago

Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug

Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease
SNY

BioPharma Dive

10 days ago

Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease

SNY

MT Newswires

10 days ago

Sanofi to Acquire Dren Bio's Autoimmune Treatment DR-0201 in $600 Million Deal

Sanofi to acquire Dren Bio's immunology unit
SNY

Reuters

10 days ago

Sanofi to acquire Dren Bio's immunology unit

Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
SNY

GlobeNewswire

10 days ago

Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline

Banks Aim to Sell €8.65 Billion Sanofi Buyout Debt Next Week
SNY

Bloomberg

11 days ago

Banks Aim to Sell €8.65 Billion Sanofi Buyout Debt Next Week

Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
SNY

PR Newswire

16 days ago

Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
SNY

GlobeNewswire

22 days ago

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
SNY

GlobeNewswire

22 days ago

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

CDC plans study into potential vaccines, autism connections, Reuters reports
SNY

TipRanks

22 days ago

CDC plans study into potential vaccines, autism connections, Reuters reports

Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?
SNY

Zacks

24 days ago

Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?

SNY

Morningstar Research

25 days ago

Analyst Report: Sanofi

SNY

GlobeNewswire

25 days ago

Press release: Sanofi successfully prices EUR 1.5 billion of bond issue

What Trump's next batch of tariffs could mean for pharma industry
SNY

Yahoo Finance Video

25 days ago

What Trump's next batch of tariffs could mean for pharma industry

SNY

MT Newswires

25 days ago

Berenberg Lifts Price Target on Sanofi to EUR120 From EUR115, Keeps Buy Rating

SNY

GuruFocus.com

25 days ago

Euroapi SA (EAPIF) (FY 2024) Earnings Call Highlights: Navigating Challenges and Embracing ...

Is Sanofi (SNY) The Best Immunology Stock To Buy Now?
SNY

Insider Monkey

a month ago

Is Sanofi (SNY) The Best Immunology Stock To Buy Now?

SNY

Thomson Reuters StreetEvents

a month ago

Q4 2024 Cytokinetics Inc Earnings Call

Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ...
SNY

GuruFocus.com

a month ago

Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ...

Novavax Inc (NVAX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial ...
SNY

GuruFocus.com

a month ago

Novavax Inc (NVAX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial ...

SNY

Thomson Reuters StreetEvents

a month ago

Q4 2024 Vir Biotechnology Inc Earnings Call

Novavax Q4 Loss Narrower Than Expected, Sales Beat Estimates
SNY

Zacks

a month ago

Novavax Q4 Loss Narrower Than Expected, Sales Beat Estimates

Novavax reports large quarterly revenue declines, rethinks its strategic direction
SNY

Yahoo Finance

a month ago

Novavax reports large quarterly revenue declines, rethinks its strategic direction

SNY

Investing.com

a month ago

Novavax shares up on fourth quarter earnings beat

Novavax sees royalties, reduced expenses on COVID vaccines from Sanofi partnership
SNY

Reuters

a month ago

Novavax sees royalties, reduced expenses on COVID vaccines from Sanofi partnership

Sanofi’s Sarclisa combo approved in Japan for newly diagnosed MM
SNY

Pharmaceutical Technology

a month ago

Sanofi’s Sarclisa combo approved in Japan for newly diagnosed MM

SNY

Argus Research

a month ago

The Argus High-Yield Model Portfolio

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
SNY

GlobeNewswire

a month ago

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma

Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease
SNY

Benzinga

a month ago

Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease

Sanofi, Teva add to case for new bowel disease drug
SNY

BioPharma Dive

a month ago

Sanofi, Teva add to case for new bowel disease drug

Sanofi and Teva report new outcomes from Phase IIb trial of duvakitug
SNY

Clinical Trials Arena

a month ago

Sanofi and Teva report new outcomes from Phase IIb trial of duvakitug

The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis
SNY

Zacks

a month ago

The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis

Sanofi (SNY): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts
SNY

Insider Monkey

a month ago

Sanofi (SNY): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
SNY

GlobeNewswire

a month ago

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
SNY

GlobeNewswire

a month ago

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More
SNY

Zacks

a month ago

Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More

Sanofi moves closer to selling controlling stake in $17bn-valued Opella
SNY

Pharmaceutical Technology

a month ago

Sanofi moves closer to selling controlling stake in $17bn-valued Opella

Sanofi reaches consumer health deal; Supernus antidepressant fails study
SNY

BioPharma Dive

a month ago

Sanofi reaches consumer health deal; Supernus antidepressant fails study

Challenges mount for vaccine makers
SNY

Pharma Voice

a month ago

Challenges mount for vaccine makers

Press Release: Sanofi and CD&R sign Opella share purchase agreement
SNY

GlobeNewswire

a month ago

Press Release: Sanofi and CD&R sign Opella share purchase agreement

SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
SNY

Zacks

a month ago

SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag

FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
SNY

Pharmaceutical Technology

a month ago

FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid

Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
SNY

GlobeNewswire

a month ago

Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid

Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
SNY

Zacks

a month ago

Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs

Banks on the Hook for Sanofi Buyout Face Agonizing Wait to Sell
SNY

Bloomberg

a month ago

Banks on the Hook for Sanofi Buyout Face Agonizing Wait to Sell

SNY

Morningstar Research

a month ago

Analyst Report: Sanofi

Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
SNY

GlobeNewswire

a month ago

Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

J&J stops Phase III trial of Sanofi’s E. Coli vaccine citing ‘disappointing’ results
SNY

Clinical Trials Arena

a month ago

J&J stops Phase III trial of Sanofi’s E. Coli vaccine citing ‘disappointing’ results

Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study
SNY

Benzinga

a month ago

Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study

Sanofi to take $250M charge on study failure for E. coli vaccine
SNY

BioPharma Dive

a month ago

Sanofi to take $250M charge on study failure for E. coli vaccine

Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
SNY

GlobeNewswire

a month ago

Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

Sanofi (SNY): Among the Best International Dividend Stocks to Buy Now
SNY

Insider Monkey

2 months ago

Sanofi (SNY): Among the Best International Dividend Stocks to Buy Now

SNY

Argus Research

2 months ago

Daily Spotlight: A Range of Sovereign Debt Yields

SNY

Argus Research

2 months ago

Weekly Stock List

Sanofi increases ownership stake partaking in pharma buyback trend
SNY

Pharmaceutical Technology

2 months ago

Sanofi increases ownership stake partaking in pharma buyback trend

Novo Nordisk’s haemophilia A drug stops bleeds in 74% of children
SNY

Clinical Trials Arena

2 months ago

Novo Nordisk’s haemophilia A drug stops bleeds in 74% of children

Press Release: Execution of a share buyback agreement for up to €2 billion
SNY

GlobeNewswire

2 months ago

Press Release: Execution of a share buyback agreement for up to €2 billion

Sanofi (SNY): Among the Best Foreign Dividend Stocks to Invest In Now
SNY

Insider Monkey

2 months ago

Sanofi (SNY): Among the Best Foreign Dividend Stocks to Invest In Now

SNY

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Regeneron Pharmaceuticals Inc Earnings Call

Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend
SNY

Investor's Business Daily

2 months ago

Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend

Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend
SNY

Zacks

2 months ago

Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend

MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive
SNY

Zacks

2 months ago

MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive

Sanofi kicks off share buyback plan with $3bn L’Oréal stake purchase
SNY

Pharmaceutical Technology

2 months ago

Sanofi kicks off share buyback plan with $3bn L’Oréal stake purchase

SNY

Argus Research

2 months ago

Analyst Report: Sanofi SA

SNY

Argus Research

2 months ago

Market Digest: SNY, BX, CLS, FL, GE, MSFT, NFG, SHEL, SYK, WBA, WM, WY, ABBV, BKR

Sanofi’s Sarclisa combo approved in China for multiple myeloma
SNY

Pharmaceutical Technology

2 months ago

Sanofi’s Sarclisa combo approved in China for multiple myeloma

SNY

MT Newswires

2 months ago

Sanofi to Buyback $3 Billion in Shares From L'Oreal

L’Oreal Sells €3 Billion of Sanofi Stock Back to Drugmaker
SNY

Bloomberg

2 months ago

L’Oreal Sells €3 Billion of Sanofi Stock Back to Drugmaker

Sanofi Buys Back Shares From L’Oréal for 3 Billion Euros
SNY

WWD

2 months ago

Sanofi Buys Back Shares From L’Oréal for 3 Billion Euros

Press Release: Sanofi announces buy back of shares from L’Oréal
SNY

GlobeNewswire

2 months ago

Press Release: Sanofi announces buy back of shares from L’Oréal

Sanofi reports Q4 2024 increase in net income to $916m
SNY

Pharmaceutical Technology

2 months ago

Sanofi reports Q4 2024 increase in net income to $916m

Pharma Stock Roundup: SNY and RHHBY's Q4 Earnings & More
SNY

Zacks

2 months ago

Pharma Stock Roundup: SNY and RHHBY's Q4 Earnings & More

Novartis sets ‘ambitious’ target; Skyrizi, Rinvoq sales climb
SNY

BioPharma Dive

2 months ago

Novartis sets ‘ambitious’ target; Skyrizi, Rinvoq sales climb

Sanofi SA (SNY) Q4 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Investments ...
SNY

GuruFocus.com

2 months ago

Sanofi SA (SNY) Q4 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Investments ...

Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
SNY

GlobeNewswire

2 months ago

Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant

SNY

Morningstar Research

2 months ago

Analyst Report: Sanofi

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use